利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

499 条记录 (耗时 0.033 秒)

    Human FGF-21 gene and gene expression products
    51.
    发明公开
    Human FGF-21 gene and gene expression products 审中-公开
    Menschliches FGF-21 Gen和Genexpressionsprodukte

    公开(公告)号：EP2163626A1

    公开(公告)日：2010-03-17

    申请号：EP09173569.6

    申请日：2000-11-16

    申请人： Novartis Vaccines and Diagnostics, Inc. ,  Kyoto University

    发明人： Nobuyuki, Itoh ,  Kavanaugh, Michael W.

    IPC分类号： C12N15/12 ,  C07K14/50 ,  C12N5/10 ,  C07K16/22 ,  A61K38/18

    CPC分类号： C07K14/50

    摘要： This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.

    摘要翻译： 本发明涉及人成纤维细胞生长因子（hFGF-21）及其变体，以及编码FGF-21的多核苷酸。 本发明还涉及与多核苷酸和蛋白质相关的诊断和治疗剂，包括探针和抗体，以及治疗肝脏疾病如肝硬化和癌症的方法，治疗与胸腺功能相关的病症的方法，以及治疗 睾丸。 本发明还涉及小鼠成纤维细胞生长因子（mFGF-21）及其变体和编码mFGF-21的多核苷酸。

    N-TERMINAL FGF VARIANTS HAVING INCREASED RECEPTOR SELECTIVITY AND USES THEREOF
    54.
    发明公开
    N-TERMINAL FGF VARIANTS HAVING INCREASED RECEPTOR SELECTIVITY AND USES THEREOF 有权
    具有增加的受体选择性的N-末端FGF变体及其用途

    公开(公告)号：EP2083846A2

    公开(公告)日：2009-08-05

    申请号：EP07827173.1

    申请日：2007-10-07

    申请人： Hepacore Ltd.

    发明人： YAYON, Avner ,  ROM, Eran ,  CHUMAKOV, Irina ,  BLUMENSTEIN, Sara

    IPC分类号： A61K38/18 ,  C07K14/50 ,  C12N1/21 ,  C12N5/10 ,  C12N15/18 ,  C12N15/63

    CPC分类号： C07K14/503 ,  A61K38/00 ,  A61K38/1825 ,  C07K14/50

    摘要： The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides that include a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions of the same and methods for use thereof.

    摘要翻译： 本发明涉及具有改善的受体特异性的成纤维细胞生长因子（FGF）多肽的设计，制造和用途。 具体而言，本发明涉及包含截短的N-端和任选的N-端氨基酸取代的分离的FGF2和FGF4多肽。 本发明提供了多肽，编码所述多肽的核酸，包含其的组合物及其使用方法。

    GLP-1 ANALOG FUSION PROTEIN FORMULATIONS
    56.
    发明授权
    GLP-1 ANALOG FUSION PROTEIN FORMULATIONS 有权
    配方GLP-1类似物融合蛋白

    公开(公告)号：EP1831252B1

    公开(公告)日：2009-07-01

    申请号：EP05854150.9

    申请日：2005-12-15

    申请人： ELI LILLY AND COMPANY

    发明人： GLAESNER, Wolfgang ,  MILLICAN, Rohn, Lee, Junior

    IPC分类号： C07K14/50 ,  C07K14/605 ,  A61K38/26 ,  A61P3/10 ,  C12N15/62 ,  C07K14/435 ,  A61K38/00

    CPC分类号： C07K14/605 ,  C07K2319/30

    摘要： The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1-Fc fusions at a pH outside the described ranges. The formulations comprising a GLP-1-Fc fusion are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.

    NOVEL PEPTIDE AND USE THEREOF
    57.
    发明公开
    NOVEL PEPTIDE AND USE THEREOF 有权
    新的肽类和使用

    公开(公告)号：EP1976864A1

    公开(公告)日：2008-10-08

    申请号：EP06702901.7

    申请日：2006-01-23

    申请人： Imagene Co., Ltd.

    发明人： KIM, Sung-hoon ,  HAN, Jung-min

    IPC分类号： C07K14/00 ,  C07K14/50

    CPC分类号： C07K14/47

    摘要： The present invention relates to a novel peptide and use thereof, more particularly to an isolated peptide comprising 21-41 contiguous amino acids selected from the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence having at least 90% sequence homology to the amino acid sequence of SEQ ID NO: 1 and methods for promoting fibroblast proliferation and wound healing, which comprise administering to a subject in need thereof an effective amount of the peptide.

    Fibroblast growth factor-23 molecules and uses thereof
    58.
    发明公开
    Fibroblast growth factor-23 molecules and uses thereof 审中-公开
    Fibroblastenwachstumsfaktor-23-Moleküleund ihre Verwendung

    公开(公告)号：EP1947182A1

    公开(公告)日：2008-07-23

    申请号：EP07017423.0

    申请日：2001-02-15

    申请人： Amgen Inc.

    发明人： Luethy, Roland ,  Suggs, Sidney ,  Sarosi, Iidiko ,  Yang, Robert

    IPC分类号： C12N15/12 ,  C12N15/62 ,  C12N15/86 ,  C07K14/50 ,  C07K16/22 ,  C12Q1/68 ,  A61K9/00 ,  A61K38/18 ,  A01K67/027 ,  G01N33/68

    CPC分类号： C07K14/50 ,  A61K38/00 ,  G01N33/6872 ,  G01N2333/50

    摘要： The present invention provides Fibroblast Growth Factor-23 (FGF-23) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGF-23 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGF-23 polypeptides.

    摘要翻译： 本发明提供成纤维细胞生长因子-23（FGF-23）多肽和编码该多肽的核酸分子。 本发明还提供选择性结合剂，载体，宿主细胞和用于产生FGF-23多肽的方法。 本发明进一步提供用于诊断，治疗，改善和/或预防与FGF-23多肽相关的疾病，病症和病症的药物组合物和方法。

    GLP-1 ANALOG FUSION PROTEIN FORMULATIONS
    59.
    发明公开
    GLP-1 ANALOG FUSION PROTEIN FORMULATIONS 有权
    配方GLP-1类似物融合蛋白

    公开(公告)号：EP1831252A1

    公开(公告)日：2007-09-12

    申请号：EP05854150.9

    申请日：2005-12-15

    申请人： ELI LILLY AND COMPANY

    发明人： GLAESNER, Wolfgang ,  MILLICAN, Rohn, Lee, Junior

    IPC分类号： C07K14/50 ,  C07K14/605 ,  A61K38/26 ,  A61P3/10 ,  C12N15/62 ,  C07K14/435 ,  A61K38/00

    CPC分类号： C07K14/605 ,  C07K2319/30

    摘要： The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1-Fc fusions at a pH outside the described ranges. The formulations comprising a GLP-1-Fc fusion are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.